AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs
With JAK inhibitors Under A Cloud Of Scrutiny Over Safety, FDA Seeks More Benefit-Risk Data
The expansion of upadacitinib for a new indication in psoriatic arthritis has been pushed out three months to late in the second quarter.
